SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
KNSA reported Third Quarter 2026 results. The stock moved +22.2% on the print.
KNSAearnings

Earnings reactions, page 11

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 FY2026 earnings

October 27, 2026 · SharpeIQ Research Desk

Reported results

  • ARCALYST net product revenue was $286.0 million for the third quarter of 2026.
  • Total operating expenses for the third quarter of 2026 were $231.7 million.
  • Net income for the third quarter of 2026 was $47.3 million.
  • Total operating expenses for the third quarter of 2026 included $13.1 million in non-cash, share-based compensation expense.
  • As of September 30, 2026, Kiniksa had $568.8 million of cash, cash equivalents, and short-term investments.

Guidance

  • Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion.
  • Kiniksa expects 2026 R&D expenses of between $160 million and $170 million.
  • Kiniksa expects 2026 SG&A expenses of between $270 million and $280 million.
  • Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.

Price and volatility reaction

The stock moved +22.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +59.5 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release72.982026-10-26
Close after release89.22026-10-27
Realised move+22.2%close to close
30d ATM IV change+59.5 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →